(Reuters) – Vertex Pharmaceuticals and its partner CRISPR Therapeutics said on Friday their sickle cell disease gene therapy Casgevy would be available at a list price of $2.2 million in the United States.
Bluebird bio said it has set a list price of $3.1 million for its treatment, Lyfgenia, for the condition.
Both the therapies were approved by the U.S. health regulator earlier on Friday.
(Reporting by Bhanvi Satija in Bengaluru)
